We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CONSTELLA (Allergan Australia Pty Ltd)
Product name
CONSTELLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
245 working days (255)
Active ingredients
linaclotide
Registration type
NCE/NBE
Indication
CONSTELLA (hard capsules) is indicated in adults for the treatment of:
- irritable bowel syndrome with constipation (IBS-C) and
- chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.